SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors

Brings executive, operational, business development and commercial leadership expertise based on over 30 years in the biopharmaceutical industry

JERSEY CITY, N.J., Jan. 22, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Armando Anido to its Board of Directors. Mr. Anido currently serves as Chairman and Chief Executive Officer of Zynerba Pharmaceuticals (NASDAQ: ZYNE), a role he has held since October 2014.

"2018 was a critical year for our company with the positive results of our Phase 2 DOVE study in VVC, and we enter 2019 in a position of strength with ongoing clinical activities for oral ibrexafungerp in a variety of indications," said Guy Macdonald, Chairman of the Board of SCYNEXIS. "As we near an initial NDA filing in VVC, anticipated in the second half of 2020, and as we continue developing treatments for hospital-based invasive fungal infections, we are excited to leverage Armando's broad expertise, insights and guidance. On behalf of my fellow Board members, I would like to welcome Armando and look forward to his contributions as we carry out the important work of bringing novel antifungal treatments to patients."

"I am impressed by SCYNEXIS's progress to date and honored to join its Board at this exciting and transformative moment, as SCYNEXIS advances ibrexafungerp across multiple indications with a clear opportunity to address serious unmet medical needs," said Mr. Anido. "Given its late-stage asset and experienced leadership team, the company is well positioned to bring significant value to all key stakeholders – patients, physicians and investors. SCYNEXIS is poised to make the first significant advancement in more than two decades in the fight against severe fungal infections, and I am looking forward to working with such an impressive team and contributing to the company's future success."

Mr. Anido has served as Chairman and Chief Executive Officer (CEO) of Zynerba Pharmaceuticals since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry.  Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe Inc., which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before the company's acquisition by Teva. He also served as President and CEO of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Under Mr. Anido's leadership at Auxilium, sales grew from $42 million in 2005 to more than $260 million in 2011. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, where Synagis, an anti-viral for RSV, became a blockbuster product, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He is currently a member of the Board of Directors of AURIS Medical Holding AG and Life Science PA, and he was a member of the Board of Directors of Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit

Forward Looking Statement
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS's reliance on third parties to conduct SCYNEXIS's clinical studies. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations
Natalie Wildenradt
Argot Partners
Tel: 212-600-1902

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093

Cision View original content: